ArticleMolecular neurodegeneration advances2026
Monospecific antibodies reveal reduction of granulins in frontotemporal dementia caused by
Article in Molecular neurodegeneration advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Loss-of-function mutations in the progranulin (PGRN) gene ( Methods: We generated and validated a panel of polyclonal monospecific antibodies targeting each human granulin (GRN1-GRN7). Granulin antibodies were characterized by immunoblot, immunocytochemistry, and epitope mapping using a peptide microarray. The ability of anti-granulin antibodies to detect endogenous GRNs was evaluated in human cell lines, peripheral tissues, and postmortem brain samples from individuals with and without Results: Antibodies against GRN1, GRN2, GRN3, GRN4, and GRN7 selectively detected overexpressed and endogenous GRNs in human cell lines, with minimal cross-reactivity. Epitope mapping revealed that anti-GRN2 and GRN4 antibodies target unique linear regions that correlate with their superior performance in complex tissues. GRN2 and GRN4 were readily detectable in human brain and peripheral tissues, with the highest expression in thalamus and white matter. GRN2 and GRN4 levels were significantly reduced in postmortem frontal cortex from FTD- Conclusions: We report the development of a panel of antibodies for the detection of individual human granulins. These reagents uncover selective reductions of GRN2 and GRN4 in FTD- Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s44477-026-00055-8.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.